We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Immupharma Plc | IMM | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.285 | 8.96% | 3.465 | 16:35:06 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.20 | 3.10 | 3.60 | 3.465 | 3.18 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 04/3/2025 07:23 by goldgeezer Does this mention IMM |
Posted at 19/2/2025 18:59 by goldgeezer Pfizer might buy IMM. Their vaccine destroys the immune system and this can fix it. It's good business. Hopefully they'll buy it for USD2B |
Posted at 19/2/2025 18:17 by supernumerary I see Cabaletta's CAR-T also making good progress in lupus - IMM + Avion need to get a move on or there'll be nothing left for them.Cabaletta’s new data slice for its investigational CD19-CAR T cell therapy shows “robust benefit” for patients with lupus and dermatomyositis without the need for steroids or immunosuppressants, according to a group of analysts. The updated phase 1/2 data come from the first 10 patients dosed with resecabtagene autoleucel (rese-cel), previously known as CABA-201, which were presented at the American Association for the Advancement of Science annual meeting last week in Boston. The patients are part of Cabaletta’s RESET program across inflammatory muscle condition myositis, systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). Last month, the biotech shared safety data showing rese-cel was well tolerated among eight patients, with the new update including data on two more patients in SLE/lupus nephritis (LN), plus initial efficacy data. As of Jan. 8, 2025, 10 patients had been dosed with a one-time infusion of rese-cel and had at least one month of follow-up. In the SLE trial, three out of four patients in the non-renal cohort achieved remission as of the most recent follow-up visit. The first patient dosed in the LN group achieved a complete renal response (CRR). All six SLE and LN patients are off all immunosuppressants and steroids as of the data cut-off date. [...] |
Posted at 13/2/2025 11:41 by lord loads of lolly supernumerary - I'm assuming your post was sarcastic, seeing as only one of the past six Lanstead deals actually resulted in gains for IMM.And that was back in 2016 when the share price was riding relatively high in the build up to the first (failed) P3 trial. |
Posted at 05/2/2025 16:19 by socionomics IMM is about 5 years behind STX. No wonder punters are transitioning. |
Posted at 28/1/2025 05:38 by soulac1 https://www2.investt |
Posted at 27/1/2025 15:50 by socionomics "Cancer therapy with potential to transform lupus treatment delivered in Manchester in UK first" Nov 2024.Are IMM the only gig in town? |
Posted at 13/1/2025 11:05 by putinaire IMM @IMMinentBoom |
Posted at 10/1/2025 10:43 by putinaire Putinaire - 09 Jan 2025 - 13:28:27 - 38794 of 38908 IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES - IMMGot a feeling, this is not the biggest day at all you know ........ Not saying it's today. Dunno. But yesterday was not the big move at all |
Posted at 09/1/2025 09:21 by tomboyb I was just going to ask your opinion Nobby -IMM have data correlating to auto-immune mechanisms. And will be increasing a number of patents for P140. I presume this is specific to P140 not generic (although it sounds it) - No release of data due to patent pending? - |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
